TY - JOUR T1 - Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 891 LP - 896 DO - 10.1097/IGC.0000000000000436 VL - 25 IS - 5 AU - Shinsuke Hanawa AU - Akira Mitsuhashi AU - Hirokazu Usui AU - Noriko Yamamoto AU - Miho Watanabe-Nemoto AU - Kyoko Nishikimi AU - Takashi Uehara AU - Shinichi Tate AU - Takashi Uno AU - Makio Shozu Y1 - 2015/06/01 UR - http://ijgc.bmj.com/content/25/5/891.abstract N2 - Objectives It has been established that concurrent chemoradiotherapy (CCRT) is efficacious for cervical cancer, but adherence is unsatisfactory among elderly patients. To improve adherence, we have developed and initiated a daily low-dose cisplatin-based CCRT regimen. Here, we retrospectively evaluated the use of CCRT, especially for elderly patients.Methods The study included a total of 53 patients who were 70 years or older, had stage IB-IVA cervical cancer, and were initially treated with daily CCRT. The daily CCRT comprised pelvic external beam radiotherapy (2 Gy/d × 25) with daily low-dose cisplatin (8.0 mg/m2 per day) and either low- or high-dose-rate intracavitary brachytherapy.Results The median age was 72 years (range, 70–85 years). The median follow-up duration was 32 months (range, 2–104 months). The 3-year overall survival rate was 79.0%. Daily cisplatin chemotherapy was successfully completed in 32 (60.4%) of the 53 patients. Grade 3 or 4 neutropenia was observed in 19 patients (36%). A late complication of grade 3 rectal hemorrhage occurred in 3 patients who received high-dose-rate brachytherapy. All primary tumors responded to daily CCRT; complete response was observed in 43 patients (91.5%) and partial response was observed in 4 patients (8.5%).Conclusions Daily CCRT in patients 70 years and older had acceptable compliance and safety. Daily CCRT is suggested to be a good treatment option for elderly patients who have advanced cervical cancer and require concurrent cisplatin. ER -